ROQ vs. NSCI, IXI, OPTI, SNG, OBD, BVX, CIZ, TCF, GENF, and EVG
Should you be buying Roquefort Therapeutics stock or one of its competitors? The main competitors of Roquefort Therapeutics include NetScientific (NSCI), IXICO (IXI), OptiBiotix Health (OPTI), Synairgen (SNG), Oxford BioDynamics (OBD), BiVictriX Therapeutics (BVX), Cizzle Biotechnology (CIZ), Theracryf (TCF), Genflow Biosciences (GENF), and Evgen Pharma (EVG). These companies are all part of the "biotechnology" industry.
Roquefort Therapeutics vs. Its Competitors
NetScientific (LON:NSCI) and Roquefort Therapeutics (LON:ROQ) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, media sentiment, dividends, earnings, risk, analyst recommendations, profitability and valuation.
Roquefort Therapeutics has lower revenue, but higher earnings than NetScientific. Roquefort Therapeutics is trading at a lower price-to-earnings ratio than NetScientific, indicating that it is currently the more affordable of the two stocks.
In the previous week, NetScientific's average media sentiment score of 0.00 equaled Roquefort Therapeutics'average media sentiment score.
14.7% of NetScientific shares are owned by institutional investors. Comparatively, 1.7% of Roquefort Therapeutics shares are owned by institutional investors. 42.4% of NetScientific shares are owned by company insiders. Comparatively, 20.3% of Roquefort Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
NetScientific has a beta of 1.67, suggesting that its share price is 67% more volatile than the S&P 500. Comparatively, Roquefort Therapeutics has a beta of 0.05, suggesting that its share price is 95% less volatile than the S&P 500.
NetScientific has a net margin of -182.91% compared to Roquefort Therapeutics' net margin of -57,057.07%. NetScientific's return on equity of -13.70% beat Roquefort Therapeutics' return on equity.
Summary
NetScientific beats Roquefort Therapeutics on 7 of the 10 factors compared between the two stocks.
Get Roquefort Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for ROQ and its competitors with MarketBeat's FREE daily newsletter.
Media Sentiment Over Time
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Roquefort Therapeutics Competitors List
Related Companies and Tools
This page (LON:ROQ) was last updated on 9/18/2025 by MarketBeat.com Staff
Free ROQ Stock Alerts